Lenacapavir Injection

Contraindicated

Lenacapavir Injection Apalutamide Erleada Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Carbamazepine Carbatrol Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Colchicine Colcrys Increased colchicine exposure and an increased risk of colchicine toxicity Details Lenacapavir Injection Encorafenib Braftovi Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Lenacapavir Injection Enzalutamide Xtandi Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Fosphenytoin Cerebyx Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Ivosidenib Tibsovo Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Lomitapide Increased lomitapide exposure Details Lenacapavir Injection Lumacaftor Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Mitotane Lysodren Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Phenytoin Dilantin Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Rifampin Rifadin Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Rifapentine Priftin Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection St John's Wort Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details

Major

Lenacapavir Injection Abemaciclib Verzenio Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Acalabrutinib Calquence Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Afatinib Gilotrif Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Injection Alfentanil Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Aliskiren Tekturna Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Injection Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Lenacapavir Injection Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Lenacapavir Injection Apixaban Eliquis Increased apixaban exposure and increased risk of bleeding Details Lenacapavir Injection Artemether Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Lenacapavir Injection Atazanavir Reyataz Increased lenacapavir exposure, increased atazanavir exposure and an increased risk of atazanavir-related adverse reaction Details Lenacapavir Injection Atidarsagene Autotemcel Lenmeldy Interference with the manufacturing of atidarsagene autotemcel Details Lenacapavir Injection Atogepant Qulipta Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Avanafil Stendra Increased sensitive CYP3A substrate exposure Details Lenacapavir Injection Avapritinib Ayvakit Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Benzhydrocodone Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Betrixaban Bevyxxa® Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Injection Bosentan Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Bosutinib Bosulif Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Brexpiprazole Rexulti Increased brexpiprazole exposure Details Lenacapavir Injection Budesonide Entocort Increased sensitive CYP3A substrate exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Injection Buprenorphine Belbuca Increased or reduced buprenorphine exposure Details Lenacapavir Injection Buspirone Bucapsol Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Injection Cariprazine Vraylar Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Lenacapavir Injection Cenobamate Xcopri Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lenacapavir Injection Cobicistat Tybost Increased lenacapavir exposure Details